Hits:
Indexed by:期刊论文
Date of Publication:2011-09-01
Journal:CURRENT MEDICINAL CHEMISTRY
Included Journals:Scopus、SCIE、PubMed
Volume:18
Issue:26
Page Number:4019-4028
ISSN No.:0929-8673
Key Words:HCV NS5B; benzothiadiazine scaffold-based inhibitors; 3D-QSAR; CoMFA; CoMSIA; molecular docking; molecular dynamics
Abstract:Hepatitis C virus (HCV) infection is a significant world health threat with frequently ineffective problem existed in the present treatment, thus representing a major unmet medical need. The nonstructural viral protein 5B (NS5B), one of the best-studied polymerase, has emerged as an attractive target for the development of novel therapeutics against hepatitis C virus. In this work, both ligand-and receptor-based three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were carried out using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques on 360 benzothiadiazine scaffold-based derivatives as HCV GT-1b NS5B polymerase allosteric inhibitors. The resultant optimum 3D-QSAR model exhibited R(cv)(2) of 0.54, R(ncv)(2) of 0.72 and the predictive ability was validated by using an independent test set of 90 compounds which gave R(pred)(2) value of 0.64. In addition, docking analysis and molecular dynamics simulation (MD) were also applied to elucidate the probable binding modes of these inhibitors at the allosteric site of the enzyme. Interpretation of the 3D contour maps in context of the topology of the allosteric binding site of NS5B provided insight into NS5B-inhibitor interactions. The information obtained from this work can be utilized to accurately predict the binding affinity of related analogues and also facilitate the future rational design of novel inhibitors with improved activity.
Pre One:Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y(12) Antagonists for Inhibition of Platelet Aggregation
Next One:Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors